Department of Obstetrics and Gynecology, Duke University Medical Center, Durham, North Carolina.
Obstet Gynecol. 2014 Jan;123(1):96-103. doi: 10.1097/AOG.0000000000000024.
To evaluate whether nitrofurantoin prophylaxis prevents postoperative urinary tract infection (UTI) in patients receiving transurethral catheterization after pelvic reconstructive surgery.
In a randomized, double-blind, placebo-controlled trial, participants undergoing pelvic reconstructive surgery were randomized to 100 mg nitrofurantoin or placebo once daily during catheterization if they were: 1) discharged with a transurethral Foley or performing intermittent self-catheterization; or 2) hospitalized overnight with a transurethral Foley. Our primary outcome was treatment for clinically suspected or culture-proven UTI within 3 weeks of surgery. Statistical analysis was performed by χ2 and logistic regression. Assuming 80% power at a P value of .05, 156 participants were needed to demonstrate a two-thirds reduction in UTI.
Of 159 participants, 81 (51%) received nitrofurantoin and 78 (49%) received placebo. There were no significant differences in baseline demographics, intraoperative characteristics, duration and type of catheterization, or postoperative hospitalization, except a lower rate of hysterectomy in the nitrofurantoin group. Nitrofurantoin prophylaxis did not reduce the risk of UTI treatment within 3 weeks of surgery (22% UTI with nitrofurantoin compared with 13% UTI with placebo, relative risk 1.73, 95% confidence interval 0.85-3.52, P=.12). Urinary tract infection treatment was higher in premenopausal women, lower in diabetics, and increased with longer duration of catheterization. In logistic regression adjusting for menopause, diabetes, preoperative postvoid residual volume, creatinine clearance, hysterectomy, and duration of catheterization, there was still no difference in UTI with nitrofurantoin as compared with placebo.
Prophylaxis with daily nitrofurantoin during catheterization does not reduce the risk of postoperative UTI in patients receiving short-term transurethral catheterization after pelvic reconstructive surgery.
ClinicalTrials.gov, www.clinicaltrials.gov, NCT01450800.
I.
评估在接受经尿道导尿的骨盆重建手术后的患者中,呋喃妥因预防是否可预防术后尿路感染(UTI)。
在一项随机、双盲、安慰剂对照试验中,接受骨盆重建手术的参与者,如果他们:1)经尿道 Foley 管引流出院或间歇性自行导尿;或 2)经尿道 Foley 管住院过夜,则在导尿期间每天随机接受 100mg 呋喃妥因或安慰剂。我们的主要结局是术后 3 周内治疗临床疑似或培养证实的 UTI。通过 χ2 和逻辑回归进行统计分析。假设 P 值为.05 时,80%的功效需要 156 名参与者来证明 UTI 减少三分之二。
在 159 名参与者中,81 名(51%)接受了呋喃妥因治疗,78 名(49%)接受了安慰剂治疗。两组在基线人口统计学、术中特征、导管插入时间和类型以及术后住院时间方面没有显著差异,但呋喃妥因组子宫切除术的比例较低。呋喃妥因预防并不能降低术后 3 周内 UTI 治疗的风险(呋喃妥因组 UTI 发生率为 22%,安慰剂组 UTI 发生率为 13%,相对风险 1.73,95%置信区间 0.85-3.52,P=.12)。围绝经期女性的 UTI 治疗率较高,糖尿病患者较低,导管插入时间延长则增加。在调整绝经、糖尿病、术前残余尿量、肌酐清除率、子宫切除术和导管插入时间的逻辑回归中,与安慰剂相比,呋喃妥因治疗 UTI 并无差异。
在接受骨盆重建手术后短期经尿道导尿的患者中,在导尿期间每天使用呋喃妥因预防并不能降低术后 UTI 的风险。
ClinicalTrials.gov,www.clinicaltrials.gov,NCT01450800。
I。